186 related articles for article (PubMed ID: 29916290)
1. Genetic Variation of Hepatic Enzymes Influence on β-Blocker Dose in Patients With Reduced Ejection Fraction Heart Failure.
Ingram A; Valente M
J Pharm Pract; 2020 Feb; 33(1):96-98. PubMed ID: 29916290
[TBL] [Abstract][Full Text] [Related]
2. Differences between beta-blockers in patients with chronic heart failure and chronic obstructive pulmonary disease: a randomized crossover trial.
Jabbour A; Macdonald PS; Keogh AM; Kotlyar E; Mellemkjaer S; Coleman CF; Elsik M; Krum H; Hayward CS
J Am Coll Cardiol; 2010 Apr; 55(17):1780-7. PubMed ID: 20413026
[TBL] [Abstract][Full Text] [Related]
3. Relation of ADRB1, CYP2D6, and UGT1A1 polymorphisms with dose of, and response to, carvedilol or metoprolol therapy in patients with chronic heart failure.
Baudhuin LM; Miller WL; Train L; Bryant S; Hartman KA; Phelps M; Larock M; Jaffe AS
Am J Cardiol; 2010 Aug; 106(3):402-8. PubMed ID: 20643254
[TBL] [Abstract][Full Text] [Related]
4. CYP2D6 Genetic Variation and Beta-Blocker Maintenance Dose in Patients with Heart Failure.
Luzum JA; Sweet KM; Binkley PF; Schmidlen TJ; Jarvis JP; Christman MF; Sadee W; Kitzmiller JP
Pharm Res; 2017 Aug; 34(8):1615-1625. PubMed ID: 28181117
[TBL] [Abstract][Full Text] [Related]
5. Prognostic Benefits of Carvedilol, Bisoprolol, and Metoprolol Controlled Release/Extended Release in Hemodialysis Patients with Heart Failure: A 10-Year Cohort.
Tang CH; Wang CC; Chen TH; Hong CY; Sue YM
J Am Heart Assoc; 2016 Jan; 5(1):. PubMed ID: 26738790
[TBL] [Abstract][Full Text] [Related]
6. Bisoprolol compared with carvedilol and metoprolol succinate in the treatment of patients with chronic heart failure.
Fröhlich H; Torres L; Täger T; Schellberg D; Corletto A; Kazmi S; Goode K; Grundtvig M; Hole T; Katus HA; Cleland JGF; Atar D; Clark AL; Agewall S; Frankenstein L
Clin Res Cardiol; 2017 Sep; 106(9):711-721. PubMed ID: 28434020
[TBL] [Abstract][Full Text] [Related]
7. Pharmacodynamics of beta-blockers in heart failure: lessons from the carvedilol or metoprolol European trial.
Bauman JL; Talbert RL
J Cardiovasc Pharmacol Ther; 2004 Jun; 9(2):117-28. PubMed ID: 15309248
[TBL] [Abstract][Full Text] [Related]
8. Older adults with heart failure treated with carvedilol, bisoprolol, or metoprolol tartrate: risk of mortality.
Perreault S; de Denus S; White M; White-Guay B; Bouvier M; Dorais M; Dubé MP; Rouleau JL; Tardif JC; Jenna S; Haibe-Kains B; Leduc R; Deblois D
Pharmacoepidemiol Drug Saf; 2017 Jan; 26(1):81-90. PubMed ID: 27859924
[TBL] [Abstract][Full Text] [Related]
9. Exchange of beta-blockers in heart failure patients. Experiences from the poststudy phase of COMET (the Carvedilol or Metoprolol European Trial).
Di Lenarda A; Remme WJ; Charlesworth A; Cleland JG; Lutiger B; Metra M; Komajda M; Torp-Pedersen C; Scherhag A; Swedberg K; Poole-Wilson PA;
Eur J Heart Fail; 2005 Jun; 7(4):640-9. PubMed ID: 15921806
[TBL] [Abstract][Full Text] [Related]
10. In heart failure, all beta-blockers are not necessarily equal.
Tang WH; Militello M; Francis GS
Cleve Clin J Med; 2003 Dec; 70(12):1081-7. PubMed ID: 14686687
[TBL] [Abstract][Full Text] [Related]
11. Impact of CYP2D6 Genetic Variation on the Response of the Cardiovascular Patient to Carvedilol and Metoprolol.
Lymperopoulos A; McCrink KA; Brill A
Curr Drug Metab; 2015; 17(1):30-6. PubMed ID: 26537419
[TBL] [Abstract][Full Text] [Related]
12. [Beta-adrenolytics in heart failure--are they all really equal?].
Filipiak KJ; Opolski G
Przegl Lek; 2005; 62 Suppl 2():39-42. PubMed ID: 16623117
[TBL] [Abstract][Full Text] [Related]
13. Beta-blocker choice and exchangeability in patients with heart failure and chronic obstructive pulmonary disease: an Italian register-based cohort study.
Sessa M; Mascolo A; Rasmussen DB; Kragholm K; Jensen MT; Sportiello L; Rafaniello C; Tari GM; Pagliaro C; Andersen M; Rossi F; Capuano A
Sci Rep; 2019 Aug; 9(1):11465. PubMed ID: 31391573
[TBL] [Abstract][Full Text] [Related]
14. Beta-blocker benefit according to severity of heart failure.
Bouzamondo A; Hulot JS; Sanchez P; Lechat P
Eur J Heart Fail; 2003 Jun; 5(3):281-9. PubMed ID: 12798825
[TBL] [Abstract][Full Text] [Related]
15. Carvedilol versus other beta-blockers in heart failure.
Doggrell SA
Expert Opin Investig Drugs; 2001 May; 10(5):971-80. PubMed ID: 11322870
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics and pharmacodynamics of beta blockers in heart failure.
Talbert RL
Heart Fail Rev; 2004 Apr; 9(2):131-7. PubMed ID: 15516861
[TBL] [Abstract][Full Text] [Related]
17. Beta-blocker treatment of chronic heart failure: comparison of carvedilol and metoprolol.
Maack C; Elter T; Böhm M
Congest Heart Fail; 2003; 9(5):263-70. PubMed ID: 14564145
[TBL] [Abstract][Full Text] [Related]
18. Influence of CYP2D6 genotype on metoprolol plasma concentration and beta-adrenergic inhibition during long-term treatment: a comparison with bisoprolol.
Nozawa T; Taguchi M; Tahara K; Hashimoto Y; Igarashi N; Nonomura M; Kato B; Igawa A; Inoue H
J Cardiovasc Pharmacol; 2005 Nov; 46(5):713-20. PubMed ID: 16220080
[TBL] [Abstract][Full Text] [Related]
19. [Congestive heart failure in Spain: cost-effectiveness and cost-benefit analyses of treatment with beta-blockers].
Díez Manglano J
Rev Clin Esp; 2005 Apr; 205(4):149-56. PubMed ID: 15860185
[TBL] [Abstract][Full Text] [Related]
20. Low Utilization of Beta-Blockers Among Medicare Beneficiaries Hospitalized for Heart Failure With Reduced Ejection Fraction.
Loop MS; van Dyke MK; Chen L; Safford MM; Kilgore ML; Brown TM; Durant RW; Levitan EB
J Card Fail; 2019 May; 25(5):343-351. PubMed ID: 30339796
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
